

Kisunla™ (donanemab-azbt) Referral Form



Preferred Clinic (select one):

PATIENT INFORMATION

Referral Status:

New Referral

Updated Referral

Referral Renewal

| | | |
|-------------------------|---------------------|----------------------|
| DOB: | Patient Name: | Patient Phone: |
| Patient Address: | Patient Email: | |
| NKDA Allergies: | Weight (lbs/kg): | Height: |
| ICD-10 Code (required): | ICD-10 Description: | Last Treatment Date: |
| | | Last 4 Digits SSN: |

PROVIDER INFORMATION

| | | | |
|--|-----------------------------|--------|-----------|
| Referral Coordinator Name: | Referral Coordinator Email: | | |
| Ordering Provider: | Provider NPI: | | |
| Referring Practice Name: | Phone: | Fax: | |
| Practice Address: | City: | State: | Zip Code: |
| Physician Preferred Method of Contact: | Email: | Fax: | Phone: |

NURSING

☒ Infusion to be administered per Vivo protocols.

LABORATORY ORDERS

| | | |
|------------------------------|--------------|-------------|
| <input type="checkbox"/> CBC | at each dose | every _____ |
| <input type="checkbox"/> CMP | at each dose | every _____ |
| <input type="checkbox"/> CRP | at each dose | every _____ |
| OTHER _____ | | |

PREMEDICATIONS (please write in): _____

KISUNLA THERAPY ADMINISTRATION

700 mg IV every 4 weeks x 3 doses, followed by 1400 mg every 4 weeks

****MRIs should be performed at baseline & prior to the 2nd, 3rd, 4th and 7th infusion****

REQUIRED DOCUMENTATION:

**** Medicare patients must be registered with CMS prior to treatment: <https://qualitynet.cms.gov/alzheimers-ced-registry/submission>**

REQUIRED DIAGNOSIS (Select one)

Mild Cognitive Impairment Due to Alzheimer's Disease– G31.84

Early Onset Alzheimer's Disease – G30.0

Late Onset Alzheimer's Disease – G30.1

Other Alzheimer's Disease – G30.8

Alzheimer's Disease unspecified-G30.9

Patient Demographics

Insurance Card/Information

Progress Notes Supporting DX

Current Medication List and H&P

Cognitive Assessment Score _____ (MMSE 20-28, CDR-GS 0.5 or 1)

MRI Within 1 Year

Confirmed presence of amyloid pathology

CMS Registry Confirmation ALZH- _____ (Medicare and Medicare Advantage only)

ApoE ε4 Testing (if available)

Patient has been provided ARIA Risk counseling

Provider Name (Print)

Provider Signature

Date

Email Referrals To: referrals@vivoinfusion.com OR Fax Below

Have a Question? Call (720) 902-4111

Colorado: 303-418-4679

Michigan: 833-957-2188

New York: 800-540-1852

Texas: 469-340-0044

Connecticut: 203-724-4838

Minnesota: 763-290-0903

Ohio: 216-400-0674

Virginia: 804-500-5941

Florida: 904-930-4211

Nevada: 702-489-5744

Oklahoma: 918-770-4421

Wisconsin: 414-600-5383

Massachusetts: 781-202-1629

New Jersey: 609-955-3711

Pennsylvania: 215-399-9244